AG
KRSA

Artal Group’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Artal Group’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,806
Closed -$271K – 23
2024
Q2 		$271K Sell
16,806
-3,045
-15% -$8.65K 0.01% 107
2024
Q1 		$445K Hold
19,851
– – 0.01% 105
2023
Q4 		$466K Hold
19,851
– – 0.02% 84
2023
Q3 		$475K Hold
19,851
– – 0.02% 87
2023
Q2 		$572K Hold
19,851
– – 0.02% 98
2023
Q1 		$1.21M Hold
19,851
– – 0.07% 90
2022
Q4 		$1.82M Hold
19,851
– – 0.1% 91
2022
Q3 		$2.39M Hold
19,851
– – 0.1% 85
2022
Q2 		$1.52M Hold
19,851
– – 0.08% 108
2022
Q1 		$3.08M Hold
19,851
– – 0.13% 103
2021
Q4 		$4.78M Hold
19,851
– – 0.13% 106
2021
Q3 		$8.53M Hold
19,851
– – 0.19% 87
2021
Q2 		$10.8M Buy
19,851
+6,868
+53% +$430K 0.22% 85
2021
Q1 		$5.07M Hold
12,983
– – 0.09% 122
2020
Q4 		$5.56M Hold
12,983
– – 0.12% 104
2020
Q3 		$11.1M Sell
12,983
-171
-1% -$19.6K 0.27% 74
2020
Q2 		$10.9M Sell
13,154
-143
-1% -$12K 0.3% 66
2020
Q1 		$4.93M Buy
13,297
+3,571
+37% +$255K 0.21% 74
2019
Q4 		$3.7M Hold
9,726
– – 0.14% 84
2019
Q3 		$16.5M Hold
9,726
– – 0.66% 31
2019
Q2 		$15.6M Buy
+9,726
New +$2.75M 0.63% 36

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Artal Group's KRSA Position: Q3 2024 in Review

Artal Group sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2024, closing a stake of 16,806 shares — an estimated $271K sold.

Artal Group first reported a position in KRSA in Q2 2019 and held it in 21 quarters. The position peaked at $16.5M in Q3 2019. 14 funds tracked by Wall St. Rank hold KRSA as of Q3 2024.

  • Artal Group reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 16,806 Korsana Biosciences, Inc. Common Stock shares in Q3 2024, an estimated $271K.
  • Artal Group first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 21 quarters.
  • Artal Group's Korsana Biosciences, Inc. Common Stock position peaked at $16.5M in Q3 2019.
  • 14 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.